Brind.
  1. Prelude Corporation's genomic test has been adopted in various US centers and is driving clinical decision-making, affiliated with Memorial Sloan Kettering Cancer Center.

Prelude Therapeutics' CSO, Peggy Scherle, confirmed Prelude's participation in a conference in New York City.

1 report, 1 independent Updated Oct 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Prelude Therapeutics' CSO, Peggy Scherle, confirmed Prelude's participation in a conference in New York City.

Who's involved

What this event is mainly about
Peggy Scherle

Keep exploring

Part of

Prelude Corporation's genomic test has been adopted in various US centers and is driving clinical decision-making, affiliated with Memorial Sloan Kettering Cancer Center. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped